<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem Soc Trans</journal-id><journal-id journal-id-type="iso-abbrev">Biochem. Soc. Trans</journal-id><journal-id journal-id-type="hwp">ppbiost</journal-id><journal-id journal-id-type="publisher-id">BST</journal-id><journal-title-group><journal-title>Biochemical Society Transactions</journal-title></journal-title-group><issn pub-type="ppub">0300-5127</issn><issn pub-type="epub">1470-8752</issn><publisher><publisher-name>Portland Press Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26517933</article-id><article-id pub-id-type="pmc">4613494</article-id><article-id pub-id-type="publisher-id">BST20150117</article-id><article-id pub-id-type="doi">10.1042/BST20150117</article-id><article-categories><subj-group subj-group-type="heading"><subject>Biochemical Society Focused Meetings</subject><subj-group><subject>Tribbles Pseudokinases on the Crossroads of Metabolism, Cancer, Immunity and Development</subject></subj-group></subj-group><subj-group subj-group-type="overline"><subject>Tribbles Pseudokinases on the Crossroads of Metabolism, Cancer, Immunity and Development</subject></subj-group><subj-group subj-group-type="Primary"><subject>S7</subject></subj-group></article-categories><title-group><article-title>Tribbles in normal and malignant haematopoiesis</article-title><alt-title alt-title-type="right-running-head">Tribbles pseudokinases on the cross-roads of metabolism, cancer, immunity and development</alt-title><alt-title alt-title-type="left-running-head">Biochemical Society Transactions (2015) Volume 43, part 5</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Stein</surname><given-names>Sarah&#x000a0;J.</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Mack</surname><given-names>Ethan&#x000a0;A.</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Rome</surname><given-names>Kelly&#x000a0;S.</given-names></name><xref ref-type="aff" rid="A1">*</xref></contrib><contrib contrib-type="author"><name><surname>Pear</surname><given-names>Warren&#x000a0;S.</given-names></name><xref ref-type="aff" rid="A1">*</xref><xref ref-type="corresp" rid="COR1"><sup>1</sup></xref></contrib><aff id="A1"><label>*</label>Department of Pathology and Laboratory Medicine, Institute for Immunology, Abramson Family Cancer Research Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, U.S.A.</aff></contrib-group><author-notes><corresp id="COR1"><bold><sup>1</sup>To whom correspondence should be addressed (email</bold><email>wpear@mail.med.upenn.edu</email><bold>)</bold>.</corresp></author-notes><pub-date pub-type="epub"><day>9</day><month>10</month><year>2015</year></pub-date><pub-date pub-type="ppub"><day>1</day><month>10</month><year>2015</year></pub-date><volume>43</volume><issue>5</issue><issue-id pub-id-type="display">5</issue-id><fpage>1112</fpage><lpage>1115</lpage><history><date date-type="received"><day>13</day><month>5</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; 2015 Authors; published by Portland Press Limited</copyright-statement><copyright-year>2015</copyright-year></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="bst0431112.pdf"/><abstract><p>The tribbles protein family, an evolutionarily conserved group of pseudokinases, have been shown to regulate multiple cellular events including those involved in normal and malignant haematopoiesis. The three mammalian Tribbles homologues, Trib1, Trib2 and Trib3 are characterized by conserved motifs, including a pseudokinase domain and a C-terminal E3 ligase-binding domain. In this review, we focus on the role of Trib (mammalian Tribbles homologues) proteins in mammalian haematopoiesis and leukaemia. The Trib proteins show divergent expression in haematopoietic cells, probably indicating cell-specific functions. The roles of the Trib proteins in oncogenesis are also varied and appear to be tissue-specific. Finally, we discuss the potential mechanisms by which the Trib proteins preferentially regulate these processes in multiple cell types.</p></abstract><kwd-group kwd-group-type="kwd"><kwd>haematopoiesis</kwd><kwd>leukaemia</kwd><kwd>tribbles</kwd></kwd-group><counts><fig-count count="2"/><ref-count count="36"/><page-count count="4"/></counts></article-meta></front><body><sec><title>Tribbles</title><p>Tribbles proteins belong to an evolutionarily conserved protein family that is implicated in diverse cellular events including proliferation, metabolism and oncogenic transformation. <italic>Tribbles</italic> was first characterized in <italic>Drosophila</italic> as an important cell cycle regulator [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B2" ref-type="bibr">2</xref>]. The three mammalian Tribbles homologues, Trib1, Trib2 and Trib3 [<xref rid="B3" ref-type="bibr">3</xref>] are characterized by a conserved pseudokinase domain [<xref rid="B4" ref-type="bibr">4</xref>] and a C-terminal E3 ligase-binding domain [<xref rid="B5" ref-type="bibr">5</xref>]. Tribbles proteins function as scaffolding molecules that facilitate the degradation of proteins via a proteasome-dependent mechanism. In <italic>Drosophila</italic>, <italic>tribbles</italic> mediates the degradation of the cell division cycle 25 homolog A (CDC25a) homologue <italic>string</italic>, which regulates cell cycle progression [<xref rid="B1" ref-type="bibr">1</xref>,<xref rid="B6" ref-type="bibr">6</xref>] and the CCAAT/enhancer-binding protein (C/EBP) homologue slow border cells (slbo) which functions in oocyte migration [<xref rid="B7" ref-type="bibr">7</xref>]. In mammals, Trib1 and Trib2 promote C/EBP&#x003b1; and C/EBP&#x003b2;&#x000a0;degradation by recruiting the E3 ligase, Caspase recruitment domain-containing protein 16 (CARD16, also known and defined in this article as COP1) [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B9" ref-type="bibr">9</xref>]. Similarly, Trib3 promotes COP1-dependent degradation of acetyl CoA carboxylase (ACC), an enzyme involved in fatty acid synthesis [<xref rid="B5" ref-type="bibr">5</xref>]. TRIB proteins also modulate signalling pathways such as protein kinase B (PKB, also known and defined in this article as AKT) [<xref rid="B9" ref-type="bibr">9</xref>,<xref rid="B10" ref-type="bibr">10</xref>] and Mitogen-activated protein kinase (MAPK) [<xref rid="B11" ref-type="bibr">11</xref>] (<xref ref-type="fig" rid="F1">Figure 1</xref>). However, it is unclear if these functions are related to protein degradation or alternative TRIB functions.</p><fig id="F1" position="float"><label>Figure 1</label><caption><title>The Trib family members regulate protein function</title><p>Trib proteins facilitate the degradation of C/EBP in a COP1-dependent manner. Additionally, Trib inhibits AKT phosphorylation and activates MAPK signalling.</p></caption><graphic xlink:href="bst0431112fig1"/></fig></sec><sec><title>Tribbles in normal haematopoiesis</title><p>The expression of the Trib genes in mammals is widely divergent, suggesting the compartmentalization of their function. Trib3 is largely expressed by non-haematopoietic tissues and therefore will not be discussed in this review. In contrast, both Trib1 and Trib2 are expressed in haematopoietic lineage cells; in mice, <italic>Trib1</italic> is predominantly expressed in myeloid lineage cells, whereas <italic>Trib2</italic> has a lymphoid bias [<xref rid="B12" ref-type="bibr">12</xref>]. This separation is not absolute as <italic>Trib2</italic> is moderately expressed in the common myeloid progenitor (CMP) and megakaryocyte/erythroid progenitor (MEP; <xref ref-type="fig" rid="F2">Figure 2</xref>). It is important to note that these data are derived from mRNA expression as antibodies capable of detecting endogenous expression are still being developed.</p><fig id="F2" position="float"><label>Figure 2</label><caption><title>Variable expressions of Trib1 and Trib2 mRNA in haematopoietic cells</title><p>The expression data were obtained from the Immgen database [<xref rid="B12" ref-type="bibr">12</xref>]. Red denotes high expression, blue denotes low expression.</p></caption><graphic xlink:href="bst0431112fig2"/></fig><p>Although the expression of <italic>Trib1</italic> and <italic>Trib2</italic> is largely segregated between the myeloid and lymphoid lineages, there is evidence that both affect myeloid development. It was initially noted that retroviral expression of Trib2 in murine bone marrow progenitors reduced the percentage of granulocytes and concomitantly increased the number of monocytes prior to the development of acute myeloid leukemia (AML). This phenomenon correlated with decreased C/EPB&#x003b1; p42 protein expression with minimal impact on C/EPB&#x003b1; p30 [<xref rid="B8" ref-type="bibr">8</xref>]. Although increased Trib2 expression can affect myelopoiesis, the physiological relevance of this finding is uncertain as myeloid defects have not been described in Trib2 knockout mice [<xref rid="B13" ref-type="bibr">13</xref>]. Furthermore, given the absence of Trib2 expression in the majority of myeloid progenitors and mature cells, it is unclear what affect this protein has on normal myelopoiesis.</p><p>Trib1 is expressed in myeloid cells and probably regulates development of this lineage. A recent study by Satoh et al. [<xref rid="B13" ref-type="bibr">13</xref>] examined the role of Trib1 in myeloid development in a knockout mouse model. The results showed that Trib1 loss is associated with a decrease in splenic macrophage populations, including &#x02018;M2&#x02019; biased cells [<xref rid="B13" ref-type="bibr">13</xref>]. In addition, these mice also exhibited an expanded peripheral neutrophil population and absence of eosinophils. These phenotypic changes correlated with increased C/EBP&#x003b1; protein expression, highlighting the potential importance of the interaction between Trib1 and C/EBP family members in myelopoiesis. Furthermore, these alterations promoted the development of lipodystrophy and metabolic disturbance, which could be rescued by transferring wild-type macrophages. The data, to date, suggest a role for Trib1 in physiologic myelopoiesis; however, overexpressed Trib2 may affect myelopoiesis in pathologic conditions [<xref rid="B8" ref-type="bibr">8</xref>]. C/EBP&#x003b1; appears to be connected to these phenotypes; however, this does not rule out the possibility that additional Trib-regulated signalling pathways are involved. For example, Trib proteins in mice and humans interact with the MAPK pathway [<xref rid="B11" ref-type="bibr">11</xref>,<xref rid="B14" ref-type="bibr">14</xref>], suggesting a potential role in cell proliferation. Further, Trib2 can inhibit AKT in a model of adipocyte differentiation [<xref rid="B9" ref-type="bibr">9</xref>] and Trib3 is also known to inhibit AKT activation (<xref ref-type="fig" rid="F1">Figure 1</xref>) [<xref rid="B10" ref-type="bibr">10</xref>].</p></sec><sec><title>Tribbles in leukaemia</title><sec><title>Acute myeloid leukemia</title><p>Despite the role of <italic>Drosophila</italic> tribbles as a negative regulator of the cell cycle, which suggested that it functioned as a tumour suppressor, exogenous expression of murine Trib1 or Trib2 is sufficient to induce AML <italic>in&#x000a0;vivo</italic>, a process that requires COP1-mediated proteasomal degradation of C/EBP&#x003b1; [<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>]. Deletion of C/EBP&#x003b1; resulting in its complete absence <italic>in&#x000a0;vivo</italic> leads to the development of a myeloproliferative disorder [<xref rid="B17" ref-type="bibr">17</xref>], whereas expression of the p30 C/EBP&#x003b1; isoform drives AML [<xref rid="B18" ref-type="bibr">18</xref>]. Therefore, an important function of Trib proteins in AML pathogenesis is the degradation or modification of C/EBP&#x003b1; that results in an altered ratio of the p42 and p30 C/EBP&#x003b1; isoforms. These findings are consistent with studies showing that <italic>TRIB1</italic> and <italic>TRIB2</italic> are highly expressed in molecularly-defined sub-types of human AML. However, distinct differences between TRIB1 and TRIB2 are apparent in AML pathogenesis. Mice transplanted with haematopoietic progenitors expressing Trib1 develop leukaemia more quickly (116&#x000b1;28&#x000a0;days) than those that receive cells expressing Trib2 (174&#x000b1;21&#x000a0;days) [<xref rid="B19" ref-type="bibr">19</xref>]. Additionally, increased <italic>TRIB2</italic> expression is limited to a distinct subset of AML patients in which C/EBP&#x003b1; is not mutated, but displays decreased function [<xref rid="B8" ref-type="bibr">8</xref>]. In contrast, <italic>TRIB1</italic> is highly expressed among multiple sub-types of AML that are not grouped by C/EBP&#x003b1; status including those driven by inv(16) or t(16;16) as well as M4 and M5 as compared with healthy controls [<xref rid="B20" ref-type="bibr">20</xref>,<xref rid="B21" ref-type="bibr">21</xref>].</p><p>The mechanistic role of Trib1 in AML is unclear. Trib1 is known to collaborate with HoxA7 and HoxA9 to decrease AML latency in mouse models [<xref rid="B22" ref-type="bibr">22</xref>], raising the possibility that <italic>TRIB1</italic> and <italic>HOXA7/HOXA9</italic> co-operate in human AML. Additionally, Trib1 and MEK1 interact, leading to the phosphorylation of ERK and the degradation of C/EBP&#x003b1; [<xref rid="B23" ref-type="bibr">23</xref>]. A TRIB1 gain of function mutation, R107L, was identified in human acute megakaryocytic leukaemia, the overexpression of which enhances Erk phosphorylation and accelerates the onset of AML <italic>in&#x000a0;vivo</italic> [<xref rid="B24" ref-type="bibr">24</xref>]. These data suggest that the leukaemogenic functions of TRIB1 and TRIB2 are not identical.</p></sec><sec><title>T-cell acute lymphoblastic leukemia</title><p>Trib2 was first identified as a Neurogenic Locus Notch Homolog Protein homologue 1 (NOTCH1) target in murine T-ALL [<xref rid="B8" ref-type="bibr">8</xref>,<xref rid="B25" ref-type="bibr">25</xref>] and subsequent gene expression studies show that TRIB2 is highly expressed in T-ALL [<xref rid="B21" ref-type="bibr">21</xref>]. High TRIB2 expression was identified in T-ALL and correlates with NOTCH1/FBXW7 (F-box/WD repeat-containing protein 7, which is involved in Notch turnover) mutations in paediatric cases [<xref rid="B26" ref-type="bibr">26</xref>]. Additionally, studies showed that Trib2 is also a direct transcriptional target of TAL-1 and is required for the growth and survival of human T-ALL cell lines. The studies of Sanda et al. [<xref rid="B27" ref-type="bibr">27</xref>] show that TRIB2 is oppositely regulated by the TAL1 and immunoglobulin enhancer-binding factors E12/E47 (E2A) and Transcription Factor 12 (TCF12/HEB) transcription factors, where the former activates transcription and the latter represses. Their data showing that inhibiting TRIB2 leads to apoptosis and growth arrest of multiple human T-ALL cell lines suggest that TRIB2 may be a therapeutic target in T-ALL.</p></sec></sec><sec><title>Perspectives on the oncogenic mechanisms of tribbles proteins</title><p>An oncogenic role for Trib proteins was first uncovered in a mouse model of AML. Recipients of haematopoietic progenitors overexpressing Trib2 developed AML with a median latency of 179&#x000a0;days [<xref rid="B8" ref-type="bibr">8</xref>]. Subsequent studies showed that Trib1 acts co-operatively with HoxA9 and Meis1 in a murine model of AML [<xref rid="B22" ref-type="bibr">22</xref>] and that the overexpression of Trib1, but not Trib3, in haematopoietic progenitors also induces AML <italic>in&#x000a0;vivo</italic> [<xref rid="B19" ref-type="bibr">19</xref>]. Mechanistically, the Trib proteins promote leukaemogenesis by facilitating the degradation of C/EBP&#x003b1; [<xref rid="B8" ref-type="bibr">8</xref>] through interaction with the E3 ubiquitin ligase COP1 [<xref rid="B15" ref-type="bibr">15</xref>,<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B19" ref-type="bibr">19</xref>]. Additionally, Trib1 interacts with the MAPK pathway member MEK1 to drive disease [<xref rid="B23" ref-type="bibr">23</xref>].</p><p>The Trib proteins are also implicated as oncogenic factors in solid tumours, though the role of these proteins appears to be tumour dependent. TRIB1 was shown to be essential in the growth and survival of prostate cancer cells [<xref rid="B28" ref-type="bibr">28</xref>,<xref rid="B29" ref-type="bibr">29</xref>]. Trib2 is highly expressed in melanoma cells and promotes oncogenesis by inhibiting FOXO proteins [<xref rid="B30" ref-type="bibr">30</xref>] and was identified as a potential biomarker of melanoma progression [<xref rid="B31" ref-type="bibr">31</xref>]. Additionally, Trib2 was identified as a potential driver of lung tumorigenesis through C/EBP&#x003b1; inhibition [<xref rid="B32" ref-type="bibr">32</xref>]. Trib3 is highly expressed in human lung, colon and breast tumours [<xref rid="B33" ref-type="bibr">33</xref>]. Additionally, high Trib3 expression is associated with poor prognosis in breast cancer patients [<xref rid="B34" ref-type="bibr">34</xref>].</p><p>Despite having a potential oncogenic role in leukaemia and solid tumours, Trib proteins are also implicated as tumour suppressors. A recent study by Salazar et al. [<xref rid="B35" ref-type="bibr">35</xref>] showed that the genetic deletion of Trib3 accelerated progression mouse skin papillomas, resulting in a more aggressive phenotype. The mechanism of enhanced tumorigenesis was largely dependent on the de-regulated phosphorylation of AKT and the subsequent inactivation of the FOXO3 transcription factor [<xref rid="B35" ref-type="bibr">35</xref>]. Another study showed that TRIB1 interacts with p53 to suppress its transcriptional activity by enhancing deacetylation and decreasing DNA binding, resulting in increased cell viability [<xref rid="B36" ref-type="bibr">36</xref>].</p><p>In summary, the accumulating data support an important function for Trib proteins in oncogenesis. The precise function is unlikely to be stereotypical and will probably depend on context. For example, Trib proteins have the capacity to function as both dominant oncogenes and tumour suppressors. Although Trib inhibition of C/EBP&#x003b1; may be an important mechanism in some tumour types, there are data implicating other signalling pathways, such as MAPK and AKT. Clearly, further studies are needed to identify the downstream targets of oncogenic Trib signalling as well as targets during normal haematopoiesis, which may be distinct. We anticipate that ongoing studies will reveal both the mechanisms by which Trib functions in oncogenic transformation and in which tumours it may be therapeutic target.</p></sec></body><back><fn-group><fn fn-type="presented-at"><p>Tribbles Pseudokinases on the Crossroads of Metabolism, Cancer, Immunity and Development: Held at The Aquincum Hotel, Budapest, 22&#x02013;24 April 2015</p></fn></fn-group><sec><title>Funding</title><p>This work was supported by <funding-source id="gs1">the National Institute of Health</funding-source> [grant numbers <award-id rid="gs1">T32 CA009140</award-id> (to S.J.S.), <award-id rid="gs1">T32 HL0074</award-id> and <award-id rid="gs1">T32 GM0071</award-id> (to E.A.M.) and <award-id rid="gs1">F31CA189661</award-id> (K.S.R.)]; <funding-source id="gs2">the Samuel Waxman Foundation for Cancer Research</funding-source>; <funding-source id="gs3">the Alex's Lemonade Stand Foundation</funding-source>; <funding-source id="gs4">the American Cancer Society</funding-source> [grant number <award-id rid="gs4">PF-15-065-01-TBG</award-id> (to (S.J.S.)]; <funding-source id="gs5">the National Science Foundation</funding-source> [grant number <award-id rid="gs5">DGE-1321851</award-id> (to K.S.R.)].</p></sec><glossary><title>Abbreviations</title><def-list list-content="abbreviations"><def-item><term id="uid1">AML</term><def><p>acute myeloid leukemia</p></def></def-item><def-item><term id="uid2">C/EBP</term><def><p>CCAAT/enhancer-binding protein</p></def></def-item><def-item><term id="uid3">MAPK</term><def><p>Mitogen-activated protein kinase</p></def></def-item><def-item><term id="uid4">T-ALL</term><def><p>T-cell acute lymphoblastic leukemia</p></def></def-item><def-item><term id="uid5">Trib</term><def><p>Tribbles mammalian homologue</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grosshans</surname><given-names>J.</given-names></name><name><surname>Wieschaus</surname><given-names>E.</given-names></name></person-group><article-title>A genetic link between morphogenesis and cell division during formation of the ventral furrow in <italic>Drosophila</italic></article-title><source>Cell</source><year>2000</year><volume>101</volume><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80862-4</pub-id><pub-id pub-id-type="pmid">10850494</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seher</surname><given-names>T.C.</given-names></name><name><surname>Leptin</surname><given-names>M.</given-names></name></person-group><article-title>Tribbles, a cell-cycle brake that coordinates proliferation and morphogenesis during <italic>Drosophila</italic> gastrulation</article-title><source>Curr. Biol.</source><year>2000</year><volume>10</volume><fpage>623</fpage><lpage>629</lpage><pub-id pub-id-type="doi">10.1016/S0960-9822(00)00502-9</pub-id><pub-id pub-id-type="pmid">10837248</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>K.</given-names></name><name><surname>Finley</surname><given-names>R.L.</given-names><suffix>Jr</suffix></name><name><surname>Nie</surname><given-names>D.</given-names></name><name><surname>Honn</surname><given-names>K.V.</given-names></name></person-group><article-title>Identification of 12-lipoxygenase interaction with cellular proteins by yeast two-hybrid screening</article-title><source>Biochemistry</source><year>2000</year><volume>39</volume><fpage>3185</fpage><lpage>3191</lpage><pub-id pub-id-type="doi">10.1021/bi992664v</pub-id><pub-id pub-id-type="pmid">10727209</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hegedus</surname><given-names>Z.</given-names></name><name><surname>Czibula</surname><given-names>A.</given-names></name><name><surname>Kiss-Toth</surname><given-names>E.</given-names></name></person-group><article-title>Tribbles: a family of kinase-like proteins with potent signalling regulatory function</article-title><source>Cell Signal</source><year>2007</year><volume>19</volume><fpage>238</fpage><lpage>250</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2006.06.010</pub-id><pub-id pub-id-type="pmid">16963228</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qi</surname><given-names>L.</given-names></name><name><surname>Heredia</surname><given-names>J.E.</given-names></name><name><surname>Altarejos</surname><given-names>J.Y.</given-names></name><name><surname>Screaton</surname><given-names>R.</given-names></name><name><surname>Goebel</surname><given-names>N.</given-names></name><name><surname>Niessen</surname><given-names>S.</given-names></name><name><surname>Macleod</surname><given-names>I.X.</given-names></name><name><surname>Liew</surname><given-names>C.W.</given-names></name><name><surname>Kulkarni</surname><given-names>R.N.</given-names></name><name><surname>Bain</surname><given-names>J.</given-names></name><etal/></person-group><article-title>TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism</article-title><source>Science</source><year>2006</year><volume>312</volume><fpage>1763</fpage><lpage>1766</lpage><pub-id pub-id-type="doi">10.1126/science.1123374</pub-id><pub-id pub-id-type="pmid">16794074</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mata</surname><given-names>J.</given-names></name><name><surname>Curado</surname><given-names>S.</given-names></name><name><surname>Ephrussi</surname><given-names>A.</given-names></name><name><surname>Rorth</surname><given-names>P.</given-names></name></person-group><article-title>Tribbles coordinates mitosis and morphogenesis in <italic>Drosophila</italic> by regulating string/CDC25 proteolysis</article-title><source>Cell</source><year>2000</year><volume>101</volume><fpage>511</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80861-2</pub-id><pub-id pub-id-type="pmid">10850493</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rorth</surname><given-names>P.</given-names></name><name><surname>Szabo</surname><given-names>K.</given-names></name><name><surname>Texido</surname><given-names>G.</given-names></name></person-group><article-title>The level of C/EBP protein is critical for cell migration during <italic>Drosophila</italic> oogenesis and is tightly controlled by regulated degradation</article-title><source>Mol. Cell</source><year>2000</year><volume>6</volume><fpage>23</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/S1097-2765(05)00008-0</pub-id><pub-id pub-id-type="pmid">10949024</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeshan</surname><given-names>K.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Wouters</surname><given-names>B.J.</given-names></name><name><surname>Shestova</surname><given-names>O.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Sai</surname><given-names>H.</given-names></name><name><surname>Rodriguez</surname><given-names>C.G.</given-names></name><name><surname>Maillard</surname><given-names>I.</given-names></name><name><surname>Tobias</surname><given-names>J.W.</given-names></name><name><surname>Valk</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Tribbles homolog 2 inactivates C/EBPalpha and causes acute myelogenous leukemia</article-title><source>Cancer Cell</source><year>2006</year><volume>10</volume><fpage>401</fpage><lpage>411</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2006.09.012</pub-id><pub-id pub-id-type="pmid">17097562</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naiki</surname><given-names>T.</given-names></name><name><surname>Saijou</surname><given-names>E.</given-names></name><name><surname>Miyaoka</surname><given-names>Y.</given-names></name><name><surname>Sekine</surname><given-names>K.</given-names></name><name><surname>Miyajima</surname><given-names>A.</given-names></name></person-group><article-title>TRB2, a mouse Tribbles ortholog, suppresses adipocyte differentiation by inhibiting AKT and C/EBPbeta</article-title><source>J. Biol. Chem.</source><year>2007</year><volume>282</volume><fpage>24075</fpage><lpage>24082</lpage><pub-id pub-id-type="doi">10.1074/jbc.M701409200</pub-id><pub-id pub-id-type="pmid">17576771</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>K.</given-names></name><name><surname>Herzig</surname><given-names>S.</given-names></name><name><surname>Kulkarni</surname><given-names>R.N.</given-names></name><name><surname>Montminy</surname><given-names>M.</given-names></name></person-group><article-title>TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver</article-title><source>Science</source><year>2003</year><volume>300</volume><fpage>1574</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1126/science.1079817</pub-id><pub-id pub-id-type="pmid">12791994</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiss-Toth</surname><given-names>E.</given-names></name><name><surname>Bagstaff</surname><given-names>S.M.</given-names></name><name><surname>Sung</surname><given-names>H.Y.</given-names></name><name><surname>Jozsa</surname><given-names>V.</given-names></name><name><surname>Dempsey</surname><given-names>C.</given-names></name><name><surname>Caunt</surname><given-names>J.C.</given-names></name><name><surname>Oxley</surname><given-names>K.M.</given-names></name><name><surname>Wyllie</surname><given-names>D.H.</given-names></name><name><surname>Polgar</surname><given-names>T.</given-names></name><name><surname>Harte</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Human tribbles, a protein family controlling mitogen-activated protein kinase cascades</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>42703</fpage><lpage>42708</lpage><pub-id pub-id-type="doi">10.1074/jbc.M407732200</pub-id><pub-id pub-id-type="pmid">15299019</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heng</surname><given-names>T.S.</given-names></name><name><surname>Painter</surname><given-names>M.W.</given-names></name></person-group><collab>Immunological Genome Project, C.</collab><article-title>The Immunological Genome Project: networks of gene expression in immune cells</article-title><source>Nat. Immunol.</source><year>2008</year><volume>9</volume><fpage>1091</fpage><lpage>1094</lpage><pub-id pub-id-type="doi">10.1038/ni1008-1091</pub-id><pub-id pub-id-type="pmid">18800157</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Satoh</surname><given-names>T.</given-names></name><name><surname>Kidoya</surname><given-names>H.</given-names></name><name><surname>Naito</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>M.</given-names></name><name><surname>Takemura</surname><given-names>N.</given-names></name><name><surname>Nakagawa</surname><given-names>K.</given-names></name><name><surname>Yoshioka</surname><given-names>Y.</given-names></name><name><surname>Morii</surname><given-names>E.</given-names></name><name><surname>Takakura</surname><given-names>N.</given-names></name><name><surname>Takeuchi</surname><given-names>O.</given-names></name><name><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Critical role of Trib1 in differentiation of tissue-resident M2-like macrophages</article-title><source>Nature</source><year>2013</year><volume>495</volume><fpage>524</fpage><lpage>528</lpage><pub-id pub-id-type="doi">10.1038/nature11930</pub-id><pub-id pub-id-type="pmid">23515163</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eder</surname><given-names>K.</given-names></name><name><surname>Guan</surname><given-names>H.</given-names></name><name><surname>Sung</surname><given-names>H.Y.</given-names></name><name><surname>Ward</surname><given-names>J.</given-names></name><name><surname>Angyal</surname><given-names>A.</given-names></name><name><surname>Janas</surname><given-names>M.</given-names></name><name><surname>Sarmay</surname><given-names>G.</given-names></name><name><surname>Duda</surname><given-names>E.</given-names></name><name><surname>Turner</surname><given-names>M.</given-names></name><name><surname>Dower</surname><given-names>S.K.</given-names></name><etal/></person-group><article-title>Tribbles-2 is a novel regulator of inflammatory activation of monocytes</article-title><source>Int. Immunol.</source><year>2008</year><volume>20</volume><fpage>1543</fpage><lpage>1550</lpage><pub-id pub-id-type="doi">10.1093/intimm/dxn116</pub-id><pub-id pub-id-type="pmid">18952906</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keeshan</surname><given-names>K.</given-names></name><name><surname>Bailis</surname><given-names>W.</given-names></name><name><surname>Dedhia</surname><given-names>P.H.</given-names></name><name><surname>Vega</surname><given-names>M.E.</given-names></name><name><surname>Shestova</surname><given-names>O.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Toscano</surname><given-names>K.</given-names></name><name><surname>Uljon</surname><given-names>S.N.</given-names></name><name><surname>Blacklow</surname><given-names>S.C.</given-names></name><name><surname>Pear</surname><given-names>W.S.</given-names></name></person-group><article-title>Transformation by Tribbles homolog 2 (Trib2) requires both the Trib2 kinase domain and COP1 binding</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>4948</fpage><lpage>4957</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-247361</pub-id><pub-id pub-id-type="pmid">20805362</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>A.</given-names></name><name><surname>Kato</surname><given-names>J.Y.</given-names></name><name><surname>Nakamae</surname><given-names>I.</given-names></name><name><surname>Yoneda-Kato</surname><given-names>N.</given-names></name></person-group><article-title>COP1 targets C/EBPalpha for degradation and induces acute myeloid leukemia via Trib1</article-title><source>Blood</source><year>2013</year><volume>122</volume><fpage>1750</fpage><lpage>1760</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-12-476101</pub-id><pub-id pub-id-type="pmid">23884858</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>D.E.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>N.D.</given-names></name><name><surname>Hetherington</surname><given-names>C.J.</given-names></name><name><surname>Darlington</surname><given-names>G.J.</given-names></name><name><surname>Tenen</surname><given-names>D.G.</given-names></name></person-group><article-title>Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><year>1997</year><volume>94</volume><fpage>569</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.2.569</pub-id><pub-id pub-id-type="pmid">9012825</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirstetter</surname><given-names>P.</given-names></name><name><surname>Schuster</surname><given-names>M.B.</given-names></name><name><surname>Bereshchenko</surname><given-names>O.</given-names></name><name><surname>Moore</surname><given-names>S.</given-names></name><name><surname>Dvinge</surname><given-names>H.</given-names></name><name><surname>Kurz</surname><given-names>E.</given-names></name><name><surname>Theilgaard-Monch</surname><given-names>K.</given-names></name><name><surname>Mansson</surname><given-names>R.</given-names></name><name><surname>Pedersen</surname><given-names>T.A.</given-names></name><name><surname>Pabst</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Modeling of C/EBPalpha mutant acute myeloid leukemia reveals a common expression signature of committed myeloid leukemia-initiating cells</article-title><source>Cancer Cell</source><year>2008</year><volume>13</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2008.02.008</pub-id><pub-id pub-id-type="pmid">18394553</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dedhia</surname><given-names>P.H.</given-names></name><name><surname>Keeshan</surname><given-names>K.</given-names></name><name><surname>Uljon</surname><given-names>S.</given-names></name><name><surname>Xu</surname><given-names>L.</given-names></name><name><surname>Vega</surname><given-names>M.E.</given-names></name><name><surname>Shestova</surname><given-names>O.</given-names></name><name><surname>Zaks-Zilberman</surname><given-names>M.</given-names></name><name><surname>Romany</surname><given-names>C.</given-names></name><name><surname>Blacklow</surname><given-names>S.C.</given-names></name><name><surname>Pear</surname><given-names>W.S.</given-names></name></person-group><article-title>Differential ability of Tribbles family members to promote degradation of C/EBPalpha and induce acute myelogenous leukemia</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>1321</fpage><lpage>1328</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-07-229450</pub-id><pub-id pub-id-type="pmid">20410507</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothlisberger</surname><given-names>B.</given-names></name><name><surname>Heizmann</surname><given-names>M.</given-names></name><name><surname>Bargetzi</surname><given-names>M.J.</given-names></name><name><surname>Huber</surname><given-names>A.R.</given-names></name></person-group><article-title>TRIB1 overexpression in acute myeloid leukemia</article-title><source>Cancer Genet. Cytogenet.</source><year>2007</year><volume>176</volume><fpage>58</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.cancergencyto.2007.03.003</pub-id><pub-id pub-id-type="pmid">17574965</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>K.L.</given-names></name><name><surname>Rishi</surname><given-names>L.</given-names></name><name><surname>Keeshan</surname><given-names>K.</given-names></name></person-group><article-title>Tribbles in acute leukemia</article-title><source>Blood</source><year>2013</year><volume>121</volume><fpage>4265</fpage><lpage>4270</lpage><pub-id pub-id-type="doi">10.1182/blood-2012-12-471300</pub-id><pub-id pub-id-type="pmid">23550039</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>G.</given-names></name><name><surname>Yamazaki</surname><given-names>Y.</given-names></name><name><surname>Takuwa</surname><given-names>M.</given-names></name><name><surname>Takahara</surname><given-names>T.</given-names></name><name><surname>Kaneko</surname><given-names>K.</given-names></name><name><surname>Kuwata</surname><given-names>T.</given-names></name><name><surname>Miyata</surname><given-names>S.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name></person-group><article-title>Trib1 and Evi1 cooperate with Hoxa and Meis1 in myeloid leukemogenesis</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>3998</fpage><lpage>4005</lpage><pub-id pub-id-type="doi">10.1182/blood-2006-08-041202</pub-id><pub-id pub-id-type="pmid">17227832</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>T.</given-names></name><name><surname>Kanno</surname><given-names>Y.</given-names></name><name><surname>Yamazaki</surname><given-names>Y.</given-names></name><name><surname>Takahara</surname><given-names>T.</given-names></name><name><surname>Miyata</surname><given-names>S.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name></person-group><article-title>Trib1 links the MEK1/ERK pathway in myeloid leukemogenesis</article-title><source>Blood</source><year>2010</year><volume>116</volume><fpage>2768</fpage><lpage>2775</lpage><pub-id pub-id-type="doi">10.1182/blood-2009-10-246264</pub-id><pub-id pub-id-type="pmid">20610816</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yokoyama</surname><given-names>T.</given-names></name><name><surname>Toki</surname><given-names>T.</given-names></name><name><surname>Aoki</surname><given-names>Y.</given-names></name><name><surname>Kanezaki</surname><given-names>R.</given-names></name><name><surname>Park</surname><given-names>M.J.</given-names></name><name><surname>Kanno</surname><given-names>Y.</given-names></name><name><surname>Takahara</surname><given-names>T.</given-names></name><name><surname>Yamazaki</surname><given-names>Y.</given-names></name><name><surname>Ito</surname><given-names>E.</given-names></name><name><surname>Hayashi</surname><given-names>Y.</given-names></name><name><surname>Nakamura</surname><given-names>T.</given-names></name></person-group><article-title>Identification of TRIB1 R107L gain-of-function mutation in human acute megakaryocytic leukemia</article-title><source>Blood</source><year>2012</year><volume>119</volume><fpage>2608</fpage><lpage>2611</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-12-324806</pub-id><pub-id pub-id-type="pmid">22294728</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wouters</surname><given-names>B.J.</given-names></name><name><surname>Jorda</surname><given-names>M.A.</given-names></name><name><surname>Keeshan</surname><given-names>K.</given-names></name><name><surname>Louwers</surname><given-names>I.</given-names></name><name><surname>Erpelinck-Verschueren</surname><given-names>C.A.</given-names></name><name><surname>Tielemans</surname><given-names>D.</given-names></name><name><surname>Langerak</surname><given-names>A.W.</given-names></name><name><surname>He</surname><given-names>Y.</given-names></name><name><surname>Yashiro-Ohtani</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>3706</fpage><lpage>3714</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-02-073486</pub-id><pub-id pub-id-type="pmid">17671232</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hannon</surname><given-names>M.M.</given-names></name><name><surname>Lohan</surname><given-names>F.</given-names></name><name><surname>Erbilgin</surname><given-names>Y.</given-names></name><name><surname>Sayitoglu</surname><given-names>M.</given-names></name><name><surname>O'Hagan</surname><given-names>K.</given-names></name><name><surname>Mills</surname><given-names>K.</given-names></name><name><surname>Ozbek</surname><given-names>U.</given-names></name><name><surname>Keeshan</surname><given-names>K.</given-names></name></person-group><article-title>Elevated TRIB2 with NOTCH1 activation in paediatric/adult T-ALL</article-title><source>Br. J. Haematol.</source><year>2012</year><volume>158</volume><fpage>626</fpage><lpage>634</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2141.2012.09222.x</pub-id><pub-id pub-id-type="pmid">22775572</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanda</surname><given-names>T.</given-names></name><name><surname>Lawton</surname><given-names>L.N.</given-names></name><name><surname>Barrasa</surname><given-names>M.I.</given-names></name><name><surname>Fan</surname><given-names>Z.P.</given-names></name><name><surname>Kohlhammer</surname><given-names>H.</given-names></name><name><surname>Gutierrez</surname><given-names>A.</given-names></name><name><surname>Ma</surname><given-names>W.</given-names></name><name><surname>Tatarek</surname><given-names>J.</given-names></name><name><surname>Ahn</surname><given-names>Y.</given-names></name><name><surname>Kelliher</surname><given-names>M.A.</given-names></name><etal/></person-group><article-title>Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia</article-title><source>Cancer Cell</source><year>2012</year><volume>22</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.06.007</pub-id><pub-id pub-id-type="pmid">22897851</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mashima</surname><given-names>T.</given-names></name><name><surname>Soma-Nagae</surname><given-names>T.</given-names></name><name><surname>Migita</surname><given-names>T.</given-names></name><name><surname>Kinoshita</surname><given-names>R.</given-names></name><name><surname>Iwamoto</surname><given-names>A.</given-names></name><name><surname>Yuasa</surname><given-names>T.</given-names></name><name><surname>Yonese</surname><given-names>J.</given-names></name><name><surname>Ishikawa</surname><given-names>Y.</given-names></name><name><surname>Seimiya</surname><given-names>H.</given-names></name></person-group><article-title>TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>4888</fpage><lpage>4897</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-13-3718</pub-id><pub-id pub-id-type="pmid">24962028</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>Z.Y.</given-names></name><name><surname>Huang</surname><given-names>Y.Q.</given-names></name><name><surname>Zhang</surname><given-names>Y.Q.</given-names></name><name><surname>Han</surname><given-names>Z.D.</given-names></name><name><surname>He</surname><given-names>H.C.</given-names></name><name><surname>Ling</surname><given-names>X.H.</given-names></name><name><surname>Fu</surname><given-names>X.</given-names></name><name><surname>Dai</surname><given-names>Q.S.</given-names></name><name><surname>Cai</surname><given-names>C.</given-names></name><name><surname>Chen</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>MicroRNA-224 inhibits progression of human prostate cancer by downregulating TRIB1</article-title><source>Int. J. Cancer</source><year>2014</year><volume>135</volume><fpage>541</fpage><lpage>550</lpage><pub-id pub-id-type="doi">10.1002/ijc.28707</pub-id><pub-id pub-id-type="pmid">24382668</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zanella</surname><given-names>F.</given-names></name><name><surname>Renner</surname><given-names>O.</given-names></name><name><surname>Garcia</surname><given-names>B.</given-names></name><name><surname>Callejas</surname><given-names>S.</given-names></name><name><surname>Dopazo</surname><given-names>A.</given-names></name><name><surname>Peregrina</surname><given-names>S.</given-names></name><name><surname>Carnero</surname><given-names>A.</given-names></name><name><surname>Link</surname><given-names>W.</given-names></name></person-group><article-title>Human TRIB2 is a repressor of FOXO that contributes to the malignant phenotype of melanoma cells</article-title><source>Oncogene</source><year>2010</year><volume>29</volume><fpage>2973</fpage><lpage>2982</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.58</pub-id><pub-id pub-id-type="pmid">20208562</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>R.</given-names></name><name><surname>Kalathur</surname><given-names>R.K.</given-names></name><name><surname>Colaco</surname><given-names>L.</given-names></name><name><surname>Brandao</surname><given-names>R.</given-names></name><name><surname>Ugurel</surname><given-names>S.</given-names></name><name><surname>Futschik</surname><given-names>M.</given-names></name><name><surname>Link</surname><given-names>W.</given-names></name></person-group><article-title>TRIB2 as a biomarker for diagnosis and progression of melanoma</article-title><source>Carcinogenesis</source><year>2015</year><volume>36</volume><fpage>469</fpage><lpage>477</lpage><pub-id pub-id-type="doi">10.1093/carcin/bgv002</pub-id><pub-id pub-id-type="pmid">25586991</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grandinetti</surname><given-names>K.B.</given-names></name><name><surname>Stevens</surname><given-names>T.A.</given-names></name><name><surname>Ha</surname><given-names>S.</given-names></name><name><surname>Salamone</surname><given-names>R.J.</given-names></name><name><surname>Walker</surname><given-names>J.R.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Agarwalla</surname><given-names>S.</given-names></name><name><surname>Tenen</surname><given-names>D.G.</given-names></name><name><surname>Peters</surname><given-names>E.C.</given-names></name><name><surname>Reddy</surname><given-names>V.A.</given-names></name></person-group><article-title>Overexpression of TRIB2 in human lung cancers contributes to tumorigenesis through downregulation of C/EBPalpha</article-title><source>Oncogene</source><year>2011</year><volume>30</volume><fpage>3328</fpage><lpage>3335</lpage><pub-id pub-id-type="doi">10.1038/onc.2011.57</pub-id><pub-id pub-id-type="pmid">21399661</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowers</surname><given-names>A.J.</given-names></name><name><surname>Scully</surname><given-names>S.</given-names></name><name><surname>Boylan</surname><given-names>J.F.</given-names></name></person-group><article-title>SKIP3, a novel Drosophila tribbles ortholog, is overexpressed in human tumors and is regulated by hypoxia</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>2823</fpage><lpage>2835</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1206367</pub-id><pub-id pub-id-type="pmid">12743605</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wennemers</surname><given-names>M.</given-names></name><name><surname>Bussink</surname><given-names>J.</given-names></name><name><surname>Scheijen</surname><given-names>B.</given-names></name><name><surname>Nagtegaal</surname><given-names>I.D.</given-names></name><name><surname>van Laarhoven</surname><given-names>H.W.</given-names></name><name><surname>Raleigh</surname><given-names>J.A.</given-names></name><name><surname>Varia</surname><given-names>M.A.</given-names></name><name><surname>Heuvel</surname><given-names>J.J.</given-names></name><name><surname>Rouschop</surname><given-names>K.M.</given-names></name><name><surname>Sweep</surname><given-names>F.C.</given-names></name><name><surname>Span</surname><given-names>P.N.</given-names></name></person-group><article-title>Tribbles homolog 3 denotes a poor prognosis in breast cancer and is involved in hypoxia response</article-title><source>Breast Cancer Res</source><year>2011</year><volume>13</volume><fpage>R82</fpage><pub-id pub-id-type="doi">10.1186/bcr2934</pub-id><pub-id pub-id-type="pmid">21864376</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>M.</given-names></name><name><surname>Lorente</surname><given-names>M.</given-names></name><name><surname>Garcia-Taboada</surname><given-names>E.</given-names></name><name><surname>Perez Gomez</surname><given-names>E.</given-names></name><name><surname>Davila</surname><given-names>D.</given-names></name><name><surname>Zuniga-Garcia</surname><given-names>P.</given-names></name><name><surname>Flores</surname><given-names>J.</given-names></name><name><surname>Rodriguez</surname><given-names>A.</given-names></name><name><surname>Hegedus</surname><given-names>Z.</given-names></name><name><surname>Mosen-Ansorena</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation</article-title><source>Cell Death Differ, Maria</source><year>2015</year><volume>22</volume><fpage>131</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1038/cdd.2014.133</pub-id><pub-id pub-id-type="pmid">25168244</pub-id></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miyajima</surname><given-names>C.</given-names></name><name><surname>Inoue</surname><given-names>Y.</given-names></name><name><surname>Hayashi</surname><given-names>H.</given-names></name></person-group><article-title>Pseudokinase Tribbles 1 (TRB1) negatively regulates tumor-suppressor activity of p53 through p53 deacetylation</article-title><source>Biol. Pharm. Bull.</source><year>2015</year><volume>38</volume><fpage>618</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1248/bpb.b15-00003</pub-id><pub-id pub-id-type="pmid">25832642</pub-id></element-citation></ref></ref-list></back></article>